The Role of Neutrophil to Lymphocyte Ratio in Predicting the Response to Neoadjuvant Targeted Therapies in HER2-Positive Breast Cancer
Predictive Value of NLR in HER2-Positive Breast Cancer
DOI:
https://doi.org/10.54393/pjhs.v7i3.3773Keywords:
Neutrophil-to-Lymphocyte Ratio, HER2-Positive Breast Cancer, Neoadjuvant Therapy, Pathologic Complete Response, Adjusted Odds RatiosAbstract
The neutrophil-lymphocyte ratio (NLR) is a basic systemic inflammatory biomarker, previously associated with treatment response in different forms of cancer. Its predictive importance on response to neoadjuvant HER2-targeted therapies in HER2-positive breast cancer has not been well-established, especially in Pakistani patients. Objectives: To identify the relationship between pretreatment NLR and response to neoadjuvant HER2-targeted therapy in women with HER2-positive breast cancer. Methods: This was a descriptive study carried out in Khyber Teaching Hospital. Non-probability consecutive sampling was used to enroll 120 patients. Standard neoadjuvant HER2-targeted therapy was given to patients, and after 12 weeks, treatment response was evaluated based on Miller-Payne criteria. SPSS version 25.0 was used to analyze data. Chi-square/Fisher exact tests were used to establish associations between NLR and treatment response, and multivariate logistic regression was used to determine independent predictors of complete response. Results: Out of the 120 patients, 70 (58.3%) patients had low NLR, and 50 (41.7%) patients had high NLR. Full response was obtained in 16 (22.9%) low (NLR) and 4 (8%) high (NLR) (p=0.004) patients, respectively. High NLR was an independent predictor of reduced odds of complete response using logistic regression (p=0.035). Conclusions: A low pretreatment NLR is linked to better response rates to neoadjuvant HER2-targeted therapy, which indicates its potential use as a cost-efficient biomarker in informing decisions on the use of treatment strategies in the management of patients with HER2-positive breast cancer.
References
Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast. 2022 Dec; 66: 15-23. doi: 10.1016/j.breast.2022.08.010. DOI: https://doi.org/10.1016/j.breast.2022.08.010
Freihat O, Sipos D, Kovacs A. Global Burden and Projections of Breast Cancer Incidence and Mortality to 2050: A Comprehensive Analysis of GLOBOCAN Data. Frontiers in Public Health. 2025 Oct; 13: 1622954. doi: 10.3389/fpubh.2025.1622954. DOI: https://doi.org/10.3389/fpubh.2025.1622954
Ferrando-Díez A, Felip E, Pous A, Bergamino Sirven M, Margelí M. Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. Cancers. 2022 Jul; 14(14): 3305. doi: 10.3390/cancers14143305. DOI: https://doi.org/10.3390/cancers14143305
Corti C, Giugliano F, Nicolo E, Tarantino P, Criscitiello C, Curigliano G. HER2-low Breast Cancer: A New Subtype? Current Treatment Options in Oncology. 2023 May; 24(5): 468-478. doi: 10.1007/s11864-023-01068-1. DOI: https://doi.org/10.1007/s11864-023-01068-1
Gunasekara AD, Anothaisintawee T, Youngkong S, Ha NT, McKay GJ, Attia J et al. Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis. Cancers. 2022 Jan; 14(3): 523. doi: 10.3390/cancers14030523. DOI: https://doi.org/10.3390/cancers14030523
Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C et al. Evaluation of Pathological Complete Response as Surrogate Endpoint in Neoadjuvant Randomised Clinical Trials of Early-Stage Breast Cancer: Systematic Review and Meta-Analysis. British Medical Journal. 2021 Dec; 375: 1-13. doi: 10.1136/bmj-2021-066381. DOI: https://doi.org/10.1136/bmj-2021-066381
Bestvina CM, Waters D, Morrison L, Emond B, Lafeuille MH, Hilts A et al. Cost of Genetic Testing, Delayed Care, And Suboptimal Treatment Associated with Polymerase Chain Reaction Versus Next-Generation Sequencing Biomarker Testing for Genomic Alterations in Metastatic Non-Small Cell Lung Cancer. Journal of Medical Economics. 2024 Dec; 27(1): 292-303. doi: 10.1080/13696998.2024.2314430. DOI: https://doi.org/10.1080/13696998.2024.2314430
Cullinane C, Creavin B, O’Leary DP, O’Sullivan MJ, Kelly L, Redmond HP et al. Can The Neutrophil-To-Lymphocyte Ratio Predict Complete Pathologic Response to Neoadjuvant Breast Cancer Treatment? A Systematic Review and Meta-Analysis. Clinical Breast Cancer. 2020 Dec; 20(6): 675-681. doi: 10.1016/j.clbc.2020.05.008. DOI: https://doi.org/10.1016/j.clbc.2020.05.008
Birsin Z, Nazlı İ, Alkan O, Odabaşı Bükün H, Günaltılı M, Çerme E et al. Inflammatory and Nutritional Markers Predicting Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Multicenter Real-World Study. Journal of Clinical Medicine. 2025 Oct; 14(20): 7271. doi: 10.3390/jcm14207271. DOI: https://doi.org/10.3390/jcm14207271
Chen X, Cai Q, Deng L, Chen M, Xu M, Chen L et al. Association of Inflammatory Blood Markers and Pathological Complete Response in HER2-Positive Breast Cancer: A Retrospective Single-Center Cohort Study. Frontiers in Immunology. 2024 Nov; 15: 1465862. doi: 10.3389/fimmu.2024.1465862. DOI: https://doi.org/10.3389/fimmu.2024.1465862
Dowling GP, Daly GR, Hegarty A, Hembrecht S, Bracken A, Toomey S et al. Predictive Value of Pretreatment Circulating Inflammatory Response Markers in the Neoadjuvant Treatment of Breast Cancer: Meta-Analysis. British Journal of Surgery. 2024 May; 111(5): 132. doi: 10.1093/bjs/znae132. DOI: https://doi.org/10.1093/bjs/znae132
Chen Y, Chen K, Xiao X, Nie Y, Qu S, Gong C et al. Pretreatment Neutrophil-To-Lymphocyte Ratio Is Correlated with Response to Neoadjuvant Chemotherapy as an Independent Prognostic Indicator in Breast Cancer Patients: A Retrospective Study. BioMed Center Cancer. 2016 May; 16(1): 320. doi: 10.1186/s12885-016-2352-8. DOI: https://doi.org/10.1186/s12885-016-2352-8
Gomes LT, Morato-Conceição YT, Gambati AV, Maciel-Pereira CM, Fontes CJ. Diagnostic Value of the Neutrophil-To-Lymphocyte Ratio in Patients with Leprosy Reactions. Heliyon. 2020 Feb; 6(2): 1-6. doi: 10.1016/j.heliyon. 2020.e03369. DOI: https://doi.org/10.1016/j.heliyon.2020.e03369
Wang W, Liu Y, Zhang H, Zhang S, Duan X, Ye J et al. Prognostic value of residual cancer burden and Miller-Payne system after neoadjuvant chemotherapy for breast cancer. Gland surgery. 2021 Dec; 10(12): 3211. doi: 10.21037/gs-21-608. DOI: https://doi.org/10.21037/gs-21-608
Zhou Q, Dong J, Sun Q, Lu N, Pan Y, Han X. Role of Neutrophil-To-Lymphocyte Ratio as a Prognostic Biomarker in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy: A Meta-Analysis. British Medical Journal open. 2021 Sep; 11(9): 1-10. doi: 10.1136/bmjopen-2020-047957. DOI: https://doi.org/10.1136/bmjopen-2020-047957
Grassadonia A, Graziano V, Iezzi L, Vici P, Barba M, Pizzuti L et al. Prognostic Relevance of Neutrophil to Lymphocyte Ratio in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting. Cells. 2021 Jul; 10(7): 1685. doi: 10.3390/cells10071685. DOI: https://doi.org/10.3390/cells10071685
Soomro R and Cho N. Association of Neutrophil to Lymphocyte Ratio with Clinicopathological Features in Breast Cancer. 2021; 33(14): 93-100. doi: 10.9734/jammr/2021/v33i1430975. DOI: https://doi.org/10.9734/jammr/2021/v33i1430975
Saleem W, Zaidi SS, Rizwan S, Naviwala MS, Ahmed F, Zehra N et al. Single Center Study: Using Pre-Treatment Neutrophil to Lymphocyte Ratio as a Predictor of Outcome in Metastatic Breast Cancer Patients Treated with Cyclin Dependent Kinase 4/6 Inhibitors. Indus Journal of Bioscience Research. 2025 Jul; 3(7): 344-350. doi: 10.70749/ijbr.v3i7.1877. DOI: https://doi.org/10.70749/ijbr.v3i7.1877
Dogan E, Akay E, Eren SK, Turk G. Impact of Neutrophil to Lymphocyte Ratio on Pathological Response to Neoadjuvant Chemotherapy in Nonmetastatic Breast Cancer. Eurasian Journal of Medical Investigation. 2023 Oct; 7(4): 482. doi: 10.14744/ejmi.2023.51016. DOI: https://doi.org/10.14744/ejmi.2023.51016
Muñoz-Montaño W, Cabrera-Galeana P, Alvarado-Miranda A, Villarreal-Garza C, Mohar A, Olvera A et al. Prognostic Value of the Pretreatment Neutrophil-To-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment. Clinical Breast Cancer. 2020 Aug; 20(4): 307-316. doi: 10.1016/j.clbc.2019.12.011. DOI: https://doi.org/10.1016/j.clbc.2019.12.011
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
